Cellares

Cellares

Develops and manufactures cell therapies efficiently

About Cellares

Simplify's Rating
Why Cellares is rated
B
Rated A on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Company Size

201-500

Company Stage

Series C

Total Funding

$355M

Headquarters

South San Francisco, California

Founded

2019

Overview

Cellares focuses on developing and manufacturing cell therapies within the biotechnology sector. The company operates as an Integrated Development and Manufacturing Organization (IDMO), which means it combines the development and manufacturing processes of cell therapies in one facility, unlike traditional organizations that keep these processes separate. Cellares utilizes its proprietary "Smart Factory" technology, which features an automated single-use cartridge system. This system significantly enhances productivity, reduces costs per batch, and lowers process failure rates compared to conventional methods. Cellares serves a diverse clientele, including preclinical, clinical, and commercial entities, and has partnered with major pharmaceutical companies to automate the manufacturing of CAR-T cell therapies. The company aims to provide efficient and cost-effective manufacturing services, making it a competitive choice for businesses in the cell therapy space.

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Bristol Myers Squibb secures $380M for CAR T cell therapy manufacturing.
  • Ossama Eissa's appointment as COO strengthens Cellares' global expansion and operational efficiency.
  • Sony partnership enhances Cell Shuttle with advanced flow cytometry, improving precision and efficiency.

What critics are saying

  • Emerging competition from bluebird bio may increase market pressure on Cellares.
  • Rapid Smart Factory expansion could strain resources and affect quality control.
  • Over-reliance on Bristol Myers Squibb partnership poses risk if dynamics change.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing processes.
  • The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
  • Cell Q automates QC for up to 6,000 batches, reducing manual labor and costs.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$355M

Above

Industry Average

Funded Over

3 Rounds

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.
Series C Funding Comparison
Above Average

Industry standards

$50M
$50M
Medium
$62M
SeatGeek
$100M
Oura
$255M
Cellares

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

5%
RegMedNet
Apr 3rd, 2025
Cell therapy weekly: regulatory boost for automated cell therapy production platform

bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.

ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).

Recently Posted Jobs

Sign up to get curated job recommendations

Principal Enterprise Architect - GMP Systems

$140k - $240k/yr

Bridgewater Township, NJ, USA

QC LIMS Administrator

$90k - $210k/yr

Bridgewater Township, NJ, USA

Senior Manager - Raw Materials

$90k - $210k/yr

Bridgewater Township, NJ, USA

See All Jobs

Cellares is Hiring for 32 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Cellares's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Cellares

Cellanome

Cellanome

Foster City, California

Deepcell

Deepcell

Sunnyvale, California

Project Farma

Project Farma

Chicago, Illinois

QC LIMS Administrator

$90k - $210k/yr

Bridgewater Township, NJ, USA

Senior Manager - Raw Materials

$90k - $210k/yr

Bridgewater Township, NJ, USA

See All Jobs

Cellares is Hiring for 32 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Cellares's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Cellares

Cellanome

Cellanome

Foster City, California

Deepcell

Deepcell

Sunnyvale, California

Project Farma

Project Farma

Chicago, Illinois